Eve Q2 2026 earnings: Lower R&D narrows the net loss

Eve Holding (NYSE: EVEX; public warrants: EVEXW) reported a Q2 2026 net loss of $34.2 million, compared with $64.7 million a year earlier; quarterly revenue and EPS were not disclosed in the provided release. Lower R&D expense drove most of the improvement, while cash consumption declined partly because some Embraer-related payments were deferred to the beginning of the third quarter.

Core earnings data

Eve remains pre-operational and does not expect meaningful revenue, if any, during the aircraft development phase. Its financial results therefore continue to be driven mainly by spending on the eVTOL program and the broader urban air mobility ecosystem.

R&D expense fell by approximately 37% year over year, reflecting better-than-expected supplier contract negotiations and program development updates. SG&A was nearly unchanged: personnel and outsourced expenses declined about 5% despite an approximately 8% appreciation of the Brazilian real against the U.S. dollar, but higher depreciation offset those savings.

Lower R&D narrowed the loss, but cash timing also mattered

The lower quarterly loss did not reflect a shift away from development work. Eve said supplier engagement, eVTOL development and the allocation of Embraer engineering resources continued during the quarter. Instead, the reduction in R&D spending was attributed to supplier negotiations and program updates, with additional savings and synergies from Embraer also beginning to appear in the cost base.

The Master Service Agreement with Embraer remains the main driver of Eve’s R&D costs because Embraer performs several critical program activities. Eve also expects additional spending on development work and testing infrastructure, meaning quarterly R&D may continue to vary with contract negotiations and project timing.

Cash consumption fell to $49.4 million, but some MSA-related payments were deferred until the beginning of Q3. As a result, the Q2 decline does not fully represent the expected full-year cash-use pattern.

Liquidity and funding runway

Eve ended the quarter with $403.3 million in cash, cash equivalents and financial investments. Total liquidity was $531.3 million after including undrawn credit lines from Brazil’s National Development Bank and a grant, leaving approximately $128.0 million of the reported liquidity outside the cash and financial-investment balance.

Management believes this funding is sufficient to support operations and program investment through 2028. That runway remains closely tied to the pace of eVTOL development, testing requirements and payments under the Embraer agreement.

2026 cash-consumption guidance

Including the MSA payment deferred into Q3, Eve expects full-year 2026 cash consumption to reach $250 million, described as the midpoint of its guidance. The release did not provide the prior guidance range or indicate a change from an earlier outlook.

Risks investors need to monitor

• Pre-revenue development profile: Eve does not expect meaningful revenue, if any, during aircraft development, so results remain dependent on controlling program costs and maintaining access to funding.
• R&D and testing requirements: The company said additional development activities and testing infrastructure are still needed, which could keep research spending and cash consumption elevated.
• Payment timing: Deferred MSA payments reduced Q2 cash use but shift part of that outflow into Q3, limiting the usefulness of a single quarter’s cash-consumption figure.
• Liquidity composition: Total liquidity includes undrawn credit facilities and a grant in addition to cash and financial investments. Investors should therefore distinguish between immediately reported financial resources and other available funding sources.

Summary

Eve’s Q2 2026 net loss narrowed primarily because R&D expense declined following supplier negotiations, program updates and early Embraer-related savings. Quarterly cash consumption also improved, although deferred MSA payments contributed to the decrease. The main issues to watch are whether cost efficiencies persist as development and testing continue, how Q3 cash use absorbs the deferred payments, and whether the company remains on track for $250 million of full-year cash consumption and its stated funding runway through 2028.